person

Ravi Anand, MD

as of 2026-07-01
Monitor thisAsk about this
at a glance
Roles: Study Director
KOL signal score 0
0 publications · 0 high-value
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
Newron Pharmaceuticals
Roles
Study Director
KOL signal
0
Publications
0 (0 high-value)
Trial investigator
no

Trials led

4
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
NCT04461119Phase 2Completed
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
NCT07184619Phase 3Recruiting
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
NCT01955564Phase 1Completed
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
NCT02624167Phase 2Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
STUDY_DIRECTOR
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
trial
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
trial
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
trial
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
trial